糖尿病檢測市場：規模、細分市場、份額、法規、報銷、程序、到 2033 年的預測

進行糖尿病檢測是為了診斷糖尿病高風險的人。 用於診斷糖尿病的測試包括糖化血紅蛋白 (HbA1c) 測定、空腹血糖測定、C □測定和胰島素測定。 血紅蛋白 (HbA1c) 測量最常用於所有地區的糖尿病初步和確認篩檢。 美國糖尿病協會 (ADA) 建議對達到治療目標的患者每半年進行一次 HbA1c 檢測，對未達到治療目標的患者進行額外檢測。 對於檢查結果正常的患者，可以每3年重複篩檢一次。

糖尿病檢測分為糖化血紅素（HbA1c）檢測、空腹血糖檢測、糖化血紅素（HbA1c）實驗室檢測、糖化血紅素（HbA1c）POC檢測、胰島素檢測、C□檢測。

本報告深入探討了全球糖尿病檢測市場，提供競爭格局、SWOT 分析、到 2033 年的市場預測、COVID-19 的影響、區域和國家趨勢等。Masu。

目錄

目前上市的糖尿病檢測方法與競爭格局

• 對主要產業趨勢的見解
• 糖尿病檢測按細分市場劃分的總市場收入和 2015-2033 年市場前景
• 有關數量、平均售價和市場價值的詳細數據

全球、區域與國家見解

• 糖尿病檢測市場的SWOT分析
• 糖尿病檢測市場的競爭動態洞察與趨勢
• 各國醫療保健系統概覽
• 按國家/地區劃分的報銷政策
• 各國醫療科技的監管狀況

Abstract

Diabetes Assays Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Diabetes Assays market for the year 2020 and beyond. Diabetes Assays are performed to diagnose individuals at higher risk of developing the disease. Tests that are performed to diagnosis diabetes include glycated haemoglobin (HbA1c) assays, fasting glucose assays, c-peptide assays, and insulin assays. Haemoglobin (HbA1c) assays are the most commonly used for both initial and confirmatory screening of diabetes across all geographical regions. The American Diabetes Association (ADA) recommends HbA1c tests 2 times per year in patients who are meeting treatment goals and additional testing for patients who are not meeting their treatment goals. Screening may be repeated every three years in patients that have normal test results.

Diabetes Assays is segmented into Glycated Hemoglobin Assays (HbA1c), Fasting Glucose Assays, Glycated Hemoglobin (HbA1c) Lab Assay, Glycated Hemoglobin (HbA1c) Point of care (POC) Assay, Insulin Assays, C-Peptide Assays.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Diabetes Assays tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Diabetes Assays tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Diabetes Assays Tests market.
• Competitive dynamics insights and trends provided for Diabetes Assays Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, ALPCO Diagnostics, Bio-Rad Laboratories Inc, DiaSorin SpA, Quidelortho Corp, Sinocare Inc, Danaher Corp, F. Hoffmann-La Roche Ltd, Siemens AG, Tosoh Corp, EKF Diagnostics Holdings Plc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

• CMO executives who must have deep understanding of the Diabetes Assays market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to:

• Understand the impact of COVID-19 on Diabetes Assays market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Diabetes Assays market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Diabetes Assays market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Diabetes Assays market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.